Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]
KeywordsBladder cancer Empagliflozin SGLT2 inhibitors
Food and Drug Administration
Sodium–glucose cotransporter 2
The authors would like to thank Q. Dai from the Department of Medicine, School of Medicine, Vanderbilt University, USA, and W. Shi and S. Zhai from the Department of Pharmacy, Peking University Third Hospital, China, who contributed to the previous study.
YS was supported by the Indiana University Health–Indiana University School of Medicine Strategic Research Initiative.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
All authors contributed to data interpretation, drafted the report, and critically reviewed the report. All authors approved the final version of the manuscript.
- 1.Shaikh AMY (2017) SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia https://doi.org/10.1007/s00125-017-4434-9
- 3.Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia https://doi.org/10.1007/s00125-017-4370-8
- 4.US Food and Drug Administration (2007) Food and Drug Administration Amendments Act of 2007. Public Law 110-85. Available from www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. Accessed 12 August 2017
- 5.Kohler S, Lee J, George JT, Inzucchi SE, Zinman B (2017) Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia https://doi.org/10.1007/s00125-017-4430-0